

# Leukaemia Section

## Short Communication

### M0 acute non lymphocytic leukemia (M0-ANLL)

Jean-Loup Huret

Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France (JLH)

Published in Atlas Database: December 1999

Online updated version : <http://AtlasGeneticsOncology.org/Anomalies/M0ANLLID1057.html>

DOI: 10.4267/2042/37564

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.  
© 1999 *Atlas of Genetics and Cytogenetics in Oncology and Haematology*

#### Identity

**Alias:** Minimally differentiated acute myeloid leukemia

#### Clinics and pathology

##### *Epidemiology*

Rare: 3-5% of ANLL; med age 45 years; 20% are children; unbalanced sex ratio in the adults: 1.6 M/1 F,  $p < 0.01$ .

##### *Cytology*

Cytochemistry: negative for myeloperoxidase, positive for myeloid markers and negative for specific markers of the lymphoid or megakaryocytic lineages; immunophenotype: CD34+, HLA-DR+, CD117+ (corresponding to c-KIT), TdT+, CD7+.

##### *Prognosis*

Poor: CR in 50% of cases, med survival: 8 months.

#### Cytogenetics

##### *Cytogenetics morphological*

High percentage of complex (20%) and unbalanced karyotypes; partial or complete monosomy (5/del(5q), -

7/del(7q), or rearrangements of chromosome 5 and/or 7 in 15-20%; chromosome 11 rearrangements (11q23 in particular), and chromosome 8 involvement (+8) in 10-15%; t(9;22)(q34;q11) in 5%; normal karyotype in 20%.

#### References

Costello R, Mallet F, Chambost H, Sainty D, Arnoulet C, Gastaut JA, Olive D. The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38- leukemic progenitors. *Leukemia*. 1999 Oct;13(10):1513-8

Stasi R, Amadori S. AML-M0: a review of laboratory features and proposal of new diagnostic criteria. *Blood Cells Mol Dis*. 1999 Apr;25(2):120-9

Béné MC, Bernier M, Casasnovas RO, Castoldi G, Doekharan D, van der Holt B, Knapp W, Lemez P, Ludwig WD, Matures E, Orfao A, Schoch C, Sperling C, van 't Veer MB, on behalf of the European Group for the Immunological Characterization of Leukemias (EGIL). Acute myeloid leukemia (AML) M0: clinical characteristics and outcome. an analysis in 263 patients. *Blood* 1999;94 Suppl 1, p 67a, Abst 287

*This article should be referenced as such:*

Huret JL. M0 acute non lymphocytic leukemia (M0-ANLL). *Atlas Genet Cytogenet Oncol Haematol*. 1999; 3(4):202.